^
Association details:
| Biomarker: | SORT1 expression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | sudocetaxel zendusortide (TH 1902) (Tubulin polymerization promoter, Microtubule stabilizer, Sortilin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1313 - TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several Sortilin-positive (SORT1+) cancers
Published date:
03/10/2021
Excerpt:
Pre-clinical in vivo studies were performed in human SORT1+ tumor xenografts grown in mice including TNBC (MDA-MB-231 and HCC-70), melanoma (SK-MEL-28), colorectal (HT-29) and pancreatic (PANC-1) cancer models. Mice were treated with either TH1902 or docetaxel by IV bolus injections...In all cases, TH1902 showed more potent inhibition than Docetaxel.
